288 related articles for article (PubMed ID: 33830879)
1. Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
Xu W; Anwaier A; Ma C; Liu W; Tian X; Palihati M; Hu X; Qu Y; Zhang H; Ye D
Ann Med; 2021 Dec; 53(1):596-610. PubMed ID: 33830879
[TBL] [Abstract][Full Text] [Related]
2. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
[TBL] [Abstract][Full Text] [Related]
3. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
4. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
5. Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner.
Zhang Y; Xie Y; Feng Y; Wang Y; Xu X; Zhu S; Xu F; Feng N
Gene; 2022 Jan; 808():145966. PubMed ID: 34530089
[TBL] [Abstract][Full Text] [Related]
6. Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
Sun X; Xin S; Jin L; Zhang Y; Ye L
Bioengineered; 2022 May; 13(5):13986-13999. PubMed ID: 35758021
[TBL] [Abstract][Full Text] [Related]
7. A novel CD8
Lin F; Ke ZB; Xue YT; Chen JY; Cai H; Lin YZ; Li XD; Wei Y; Xue XY; Xu N
Inflamm Res; 2023 Aug; 72(8):1665-1687. PubMed ID: 37578544
[TBL] [Abstract][Full Text] [Related]
8. Construction of Protein-related Risk Score Model in Bladder Urothelial Carcinoma.
Luo Q; Zhang X
Biomed Res Int; 2020; 2020():7147824. PubMed ID: 32802870
[TBL] [Abstract][Full Text] [Related]
9. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Signature Development on the Basis of Macrophage Phagocytosis-Mediated Oxidative Phosphorylation in Bladder Cancer.
Qu G; Xu Y; Lu Z; Nie H; Tang C; Hou J; Wen X
Oxid Med Cell Longev; 2022; 2022():4754935. PubMed ID: 36211821
[TBL] [Abstract][Full Text] [Related]
13. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
[TBL] [Abstract][Full Text] [Related]
14. Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.
Zhao X; Tang Y; Ren H; Lei Y
Biomed Res Int; 2020; 2020():9143695. PubMed ID: 33204728
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
16. Construction of noninvasive prognostic model of bladder cancer patients based on urine proteomics and screening of natural compounds.
Wan S; Cao J; Chen S; Yang J; Wang H; Wang C; Li K; Yang L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):281-296. PubMed ID: 36562811
[TBL] [Abstract][Full Text] [Related]
17. CD8
Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
[TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
19. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
[TBL] [Abstract][Full Text] [Related]
20. Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm.
Hu S; Gu S; Wang S; Qi C; Shi C; Qian F; Fan G
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
